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Abstract
Background: Follicular lymphoma (FL) is one of the most common B-cell non-Hodgkin’s lymphoma (NHL). A subset of
FL cases transform into more aggressive malignancies, most often to diffuse large B-cell lymphoma (DLBCL); in addition,
lymphoblastic lymphoma and acute lymphoblastic leukemia (ALL) have also been rarely reported. The most common
cytogenetic abnormalities associated with FL are translocation t(14;18)(q32;q21) with BCL2 rearrangements, present in
80–90% of all FL. However, that translocation alone is insufficient to cause FL and additional genomic events specifically
leading to this kind of disease are still to be determined. The most frequently reported secondary changes are gains of
chromosomes 7p or 7q, Xp, 12q and 18q, as well as losses on 6q and mutations within BCL2 and/or BCL6 genes. The
presence of additional genomic aberrations, in particular 17p and 6q deletions is more frequent in grade 2 and 3 FL
patients and correlated with shorter survival and a higher rate of transformation into DLBCL.
Case presentation: We describe here, an adult FL grade 2 patient that had transformed to B-ALL at diagnosis.
Banding cytogenetics, refined by multi-color fluorescence in situ hybridization including array-proven multicolor banding
revealed a unique complex karyotype involving eleven chromosomes, translocation t(X;20)(p21.3;q11.2), translocation
t(3;20)(q26.2;q12), and a dicentric dic(17;18). Interestingly, the dicentric chromosome led to monosomy of the tumor
suppressor gene TP53. The case had an immunophenotype consistent with follicular center cell lymphoma according to
the World Health Organization (WHO) recommendations.
Conclusions: To the best of our knowledge, a comparable adult FL grade 2 case that transformed to B-ALL associated
with such a complex karyotype and loss of TP53 was not previously reported. Most of complex aberrations were found
simultaneously in approximately 85% of studied malignant cells and the remained cells studied were non-clonal;
mechanisms explaining this may be either multiple-step mechanisms or single step in sense of chromothripsis.
Trial registration: Identifying number: 3842. Registered 09 July 2012.
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Background
Follicular lymphoma (FL) is one of the most common B-
cell non-Hodgkin’s lymphoma (NHL) with a relatively indo-
lent clinical course, accounting for 20–30% of all NHL
cases. The overall survival rate in FL patients is 72–77% for
5 years, with a mean survival of 10 years [1]. A subset of FL
cases may transform into more aggressive malignancies;
most frequently observed is diffuse large B-cell lymphoma
(DLBCL) [2]. Furthermore, lymphoblastic lymphoma and
acute lymphoblastic leukemia (ALL) can result rarely from
an FL [2–4]. During such processes a more virulent subclo-
nal population of cells emerge, typically associated with the
loss of the follicular growth pattern, a rapidly progressive
clinical course refractory to treatment, and short survival
(commonly of less than 2 years) [5, 6]. Also, this transform-
ation is often associated with the occurrence of secondary
chromosomal aberrations [7, 8].
The process of malignant transformation provides an im-
portant model for the study of oncogenesis and a number
of recurring secondary events are recognized which may
be of mechanistic significance [9]. These include acquisi-
tion of recurrent chromosomal aberrations like loss of 17p
and gain of copy numbers at 12q, inactivation of CDKN2A
and CDKN2B, dysregulation of c-MYC and translocations,
gains and mutations involving BCL-6 [9].
The most common cytogenetic abnormalities associated
with FL are translocation t(14;18)(q32;q21) with BCL2 rear-
rangements, being present in 80–90% of all FL. Other com-
mon cytogenetic aberrations are +7, +18, and abnormalities
and gene rearrangements in 3q27–28 (BCL6), 6q23–26,
and 17p [1]. However, the translocation t(14;18)(q32;q21)
alone is insufficient to cause FL and those additional
genomic events specifically leading to disease are still to be
elucidated. Known common cytogenetic aberrations during
transformation of FL to DLBCL are translocations and rear-
rangements of the BCL2 andMYC genes [1].
Here we report a patient with an initial diagnosis of FL
grade 2 that transformed to B-ALL. Cytogenetic and
molecular cytogenetic analysis revealed a high complex
karyotype including three yet unreported chromosomal
aberrations, a stable dicentric derivative chromosome and
monoallelic loss of the tumor suppressor genes (TSG)
TP53. The patient was treated with hyper-CVAD but she
relapsed many times.
Case presentation
A 38-year-old female patient without any known personal
or familial medical background presented with a 1 month
history of fatigue, weakness, loss of weight and fever.
Physical examination and CT scan showed mild spleno-
megaly (data not shown). Initial laboratory evaluation of
peripheral blood revealed a white blood cell (WBC) of
3.1 × 109/l (15% were of blasts), red blood cells (RBC)
4.27 × 106/mm3, hemoglobin level of 11.7 g/dl and a platelet
count of 156 × 109/l. Biochemistry analyses revealed serum
lactate dehydrogenase (LDH) value was 893.2 U/l (normal
value up to 480 U/l); serum aspartate aminotrasferase
(AST) level was 42 U/l (normal up to 45 U/l); and alanine
aminotransferase (ALT) level was 122 U/l (normal up to 45
U/l). Total serum protein was within normal range at 7.1
gm/dl (normal value 6.4–8.3 gm/dl) but serum albumin
was 4.2 gm/dl (normal value 3.2–5 gm/dl). Ferritin value
was 1349 (13–150 ng/ml). Bone marrow aspiration revealed
95% of blasts. At this point the first cytogenetic and immu-
nophenotypic data were determined; simultaneously she
had been diagnosed as having B-ALL based on clinical and
pathological data. Treatment with hyper-CVAD for overall
10 months was initiated. The patient did not respond to
that treatment and suffered from hematuria, right eye
vision deterioration, gastrointestinal bleeding, and fever;
she received blood transfusion many times, and her periph-
eral blood (PB) showed pancytopenia. One month after
initiation of hyper-CVAD treatment her PB reached a short
amelioration of different cell counts (WBC, plt, RBC)
together with severe diarrhea, fatigue and weakness. One
week later the patient showed pancytopenia again with
diarrhea, severe stomach heart burn and fever. After one
month the BM smear showed less than 40% blats cells with
hypocellularity and BM suppression. She received cortisone,
and two months later BM revealed again / still pancyto-
penia, suppression and myelofibrosis. After another two
months BM regenerated and WBC count was 66 × 109/l
(90% were blasts). Nonetheless, the patient succumbed due
to unknown causes whilst under treatment. Her cousin
agreed with scientific evaluation of her case and the study
was approved by the ethical committee of the Atomic En-
ergy Commission, Damascus, Syria.
Results





(?;?),t(3;20)(?;?)[4]/46,XX[3] (Fig. 1). Further studies were
performed based on molecular cytogenetics (Fig. 1). Dual-
color-FISH (D-FISH) using specific WCP probes for chro-
mosomes 2, 3, 6, 9, 14, 17, 18, 20 and X (data not shown),
m-FISH confirmed a highly complex karyotype (Fig. 1),
CEP 17 and 18 probes showed a dicentric chromosome
leading to deletions of parts of the short arms of the
involved chromosomes (data not shown). The locus-
specific probe 17p13 (TP53) confirmed the absence of
the 17p on the dic(17;18) (Fig. 2). Finally, aMCB using
probes for the corresponding chromosomes were per-
formed; Fig. 3). Thus, the following final karyotype was
determined:







q32),del(14)(q23),+der(14)(14pter->14q23:: q26.1 ~ 2:),
t(3;20)(q26.2;q12)[4]/46,XX[3].
Flow cytometric analysis of peripheral blood specimen
characterized this case as B-lineage lymphoproliferative dis-
order most likely follicular center cell lymphoma according
to WHO recommendations. The abnormal cell population
(15%) was positive for CD45dim, HLA-DR, CD19, CD20,
CD10, CD79b, CD123, CD32, CD235a, Lambda and
expressed CD7, CD117, CD22, CD23, and CD38 heteroge-
neously. This cell population was negative for CD34,
CD103, CD5, CD11c, sIgD and sIgM.
Conclusions
We report a cytogenetically highly complex adult FL grade
2 case that transformed to B-ALL with a karyotype involv-
ing eleven chromosomes, a dicentric derivative derived
from parts of chromosomes 17 and 18 leading to partial
monosomy 17p including TSG TP53 and three yet
Fig. 1 Karyotype and chromosomal aberrations were confirmed using molecular cytogenetic approaches. a GTG-banding revealed the following karyotype
in 13/20 metaphases: 46,X,der(X)t(X;20)(?;?),t(2;9)(?;?),del(3)(q12),t(6;14)(?;?),der(9)t(X;9)(?;?),der(14)t(6;14)(?;?),del(14)(q?),+der(14)t(3;14)(?;?),+dic(17;18),-17,-
18,t(3;20)(?;?). All derivative chromosomes are marked and highlighted by arrow heads. b M-FISH confirmed that complexity of the karyotype
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unreported chromosomal aberrations: t(X;20)(p21.3;q11.2),
t(3;20)(q26.2;q12) and dic(17;18)(p11.2;p11.2).
Dicentric chromosomes are normally considered to be
instable during mitosis; an idea that was not supported
by this and previous own studies [10]. The role of dicen-
tric chromosomes in cancer [11, 12] is still a field to be
studied in more detail in future.
FL is regarded as a distinct entity by virtue of its char-
acteristic cellular composition of follicle center cells
(centroblasts and centrocytes), uniform immunophenotype
(CD10+), and common cytogenetic background displaying
the translocation t(14;18)(q32;q21) in most of the cases
[13]. Since this primary immortalizing event does not ren-
der the cells malignant, it is thought that additional second-
ary aberrations are necessary for tumorigenesis. In FL, the
most frequently reported secondary changes are gains of
chromosomes 7p or 7q, Xp, 12q and 18q, as well as losses
on 6q and possibly mutations of BCL2 and/or BCL6 genes.
The presence of additional genomic aberrations, in particu-
lar 17p and 6q deletions, is more frequent in grade 2 and 3
FL patients and correlated with shorter survival and a
higher rate of transformation into DLBCL [14, 15].
The p53 protein, encoded by TP53 tumor suppressor
gene (17p13), lies at the point of convergence of a number
of cellular stress pathways [16]. Activation induces cell
cycle arrest, DNA repair and, in irreparably damaged cells,
apoptosis [9]. Mutations of TP53 are the most commonly
Fig. 2 FISH using probes for CEP 17 (green) and TP53 (red) showed
one green and one red signals on normal chromosome 17; one green
signal on der(17) that confirmed the absence of the TP53 on dic(17;18).
Abbreviations: # = chromosome; der = derivative chromosome
Fig. 3 Array-proven multicolor banding (aMCB) results are shown. aMCB results are shown. The normal chromosomes (#) are depicted in the first
column on the left side and the derivative of the other chromosomes on the right side of normal chromosomes. The unstained regions when
suing chromosome-specific aMCB-probesets on the derivative chromosomes are shown in gray. Abbreviations: # = chromosome;
der = derivative chromosome
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observed in cancer [17]. In FL, mutations are infrequent,
while in de novo DLBCL they are more common and may
correlate with an adverse prognosis [18]. A recent study
suggests that the detection of TP53 mutations in primary
diagnostic specimens of FL without signs of transform-
ation also characterizes a patient subgroup with worse
prognosis [19].
Approximately 10–60% of FL cases transform into
DLBCL as well as Burkitt’s lymphoma, precursor B
lymphoblastic lymphoma and classical type of Hodgkin’s
lymphoma [2–4]. However, FL transforming into ALL
has been documented in a limited number of cases [3, 4,
20–23]. Some chromosomal aberrations such as gains in
chromosomes 2, 3q and 5 have been linked to higher
grade transformations and inferior survival [24].
According to the literature, translocation t(2;9) involv-
ing short and/or long arms of these chromosomes has
been reported in four FL cases to date [25]. Also, trans-
location t(X;9), deletion del(3)(q26), translocation t(6;14),
deletion del(14)(q23), translocation t(3;14) and transloca-
tion t(17;18) were previously reported in 3, 3, 3, 1, 54 and
3 FL cases, respectively [25]. Interestingly, translocation
t(X;20)(p21.3;q11.2), translocation t(3;20)(q26.2;q12) and
dicentric chromosome dic(17;18) has never been de-
scribed in FL cases. In addition, chromosomal bands such
as 2p21, 3q26.2, 6p22.3, 9p22.3, 14q32, 17p11, 18p11,
20q12 and Xp21.3 are involved in chromosomal rear-
rangements in 14, 16, 5, 19, 1170, 36, 16, 1 and 8 cases,
respectively [25]. To the best of our knowledge, a combin-
ation of all these rearrangements in one FL case was not
previous reported [25]; the present case report is the first
one to observe an adult FL transformed to B-ALL with
high complexly karyotype.
Al-Tourah et al. [26] established a clinical diagnosis of
transformation based on the presence of at least one of
the following: sudden rise in LDH, rapid discordant local-
ized nodal growth, new involvement of unusual extranodal
sites, new B symptoms can be observed in 30–56% of FL
patients and de novo hypercalcemia. However, clinical cri-
teria may not correctly identify all the patients, since some
of these symptoms may be associated with FL progression
without histological evidence of transformation, while in
other cases transformation may not be associated with any
of these symptoms [27]. Moreover, FL transformation can
also be diagnosed in the absence of all these clinical fea-
tures at the time of a clinically asymptomatic FL relapse
manifested by reappearance of enlarged lymph nodes [27].
The median time from diagnosis to transformation in the
reported series ranges from 40 to 66 months, with the earli-
est transformation reported at 2 months and the latest at
25 years [26, 28, 29]. Transformation may occur at the time
of the first or any of the subsequent progressions or recur-
rences in patients undergoing either expectant follow-up or
during and after therapy [27]. Most studies have reported a
poor prognosis after transformation with a median duration
of survival ranging from 2.5 months to 2 years [27].
Chromothripsis represents one subtype of genomic
chaos with highly rearranged chromosomes affecting one
or a small number of chromosomes and it was detected in
1% of blood cancers [30]. Genome chaos likely plays a role
in the evolution of most cancers [30]. Liu et al. [31]
proposed that genome chaos is a common dynamic con-
tributor to cancer progression. However, chromothripsis
is not necessarily detectable in all tumors at all stages, it
likely occurs during transitional phases (immortalization,
transformation, tumor formation, metastasis, and drug re-
sistance) of cancer evolution and is often eliminated or re-
duced during or after these transitions [32].
In conclusion, we described here a de novo adult FL
grade 2 that transformed to B-ALL at diagnosis with a
unique complex karyotype involving monosomy TSG TP53
and three novel uncommon chromosomal aberrations
t(X;20)(p21.3;q11.2), t(3;20)(q26.2;q12) and dic(17;18)(p11
.2;p11.2). The patient was treated with hyper-CVAD but
she relapsed many times. All findings including monosomy




Chromosome analysis using GTG-banding according to
standard procedures [33] was performed before the treat-
ment started. 20 metaphase cells derived from unstimu-
lated bone marrow culture were analyzed. Karyotype was
described according to the International System for
Human Cytogenetic Nomenclature (ISCN 2013) [34].
Molecular cytogenetics
Fluorescence in situ hybridization (FISH) using whole
chromosome painting (WCP) probes for chromosomes
2, 3, 6, 9, 14, 17, 18, 20 and X (MetaSystems, Altlus-
sheim, Germany), centromere-specific probes (CEP) for
chromosomes 17 and 18 (Abbott Molecular/Vysis,
USA), and a specific probe for 17p13 (TP53) (Q-Bio-
gene, USA) were applied according to manufacturer’s in-
structions [33]. Multicolor FISH (m-FISH) and FISH
using the corresponding chromosome 2, 3, 6, 17, 18 and
X specific array-proven multicolor banding (aMCB)
probe sets was performed as previously reported [35]. A
minimum of 10 metaphase spreads was analyzed, using
a fluorescence microscope (AxioImager.Z1 mot, Carl
Zeiss Ltd., Hertfordshir, UK) equipped with appropriate
filter sets to discriminate between a maximum of five
fluorochromes plus the counterstain DAPI (4′,6-
diamino-2-phenylindole). Image capture and processing
were performed using an ISIS imaging system
(MetaSystems).
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Flow cytometric immunophenotype
Immunophenotyping was done using a general panel of
fluorescent antibodies against the following antigens typ-
ical for different cell lineages and cell types: CD1a, CD2,
CD3, CD4, CD5, CD8, CD10, CD11b, CD11c, CD13,
CD14, CD15, CD16, CD19, CD20, CD22, CD23, CD32,
CD33, CD34, CD38, CD41a, CD45, CD56, CD57, CD64,
CD103, CD117, CD123, CD138, CD209, CD235a and
CD243; in addition antibodies to Kappa and Lambda light
Chains, IgD, sIgM, and HLADr were tested. All antibodies
were purchased from BD Biosciences. Samples were ana-
lyzed on a BD FACSCalibur™ flow cytometer. Autofluores-
cence, viability, and isotype controls were included. Flow
cytometric data acquisition and analysis were conducted
by BD Cellquest™ Pro software.
Abbreviations
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